RT Journal Article
A1 Bennedjai, Amin
A1 Houillier, Caroline 
A1 Choquet, Sylvain
A1 Cassoux, Nathalie
A1 guesquières, hervé
A1 marroleau, jean-pierre
A1 Bodaghi, Bahram
A1 LeHoang, Phuc 
A1 Jdid, Ibrahim
A1 Chabrot, Cécile
A1 Soussain, Carole
A1 Hoang Xuan, Khe
A1 Touitou, Valérie
T1 High-dose chemotherapy with autologus hematopoietic stem cell transplantation in relapsing Vitreoretinal Lymphoma. A LOC network study.
JF Investigative Ophthalmology & Visual Science
JO Invest. Ophthalmol. Vis. Sci.
YR 2017
VO 58
IS 8
SP 521
OP 521
SN 1552-5783
AB    Because of the rarity of the disease, the management of isolated vitreoretinal lymphoma (VRL) remains controversial. VRL prognosis remains severe, mainly because of the risk of central nervous system lymphoma development. The objective of this study is to evaluate the efficiency and safety of high-dose chemotherapy with autologous hematopoietic stem cell transplantation (HCT-ASCT) for the treatment of recurrent relapsing VRL.    We retrospectively reviewed medical records of patients seen by the French LOC network between 2007 and 2016 with isolated vitreoretinal relapse of either primary vitreoretinal lymphoma, oculocerebral lymphoma, or systemic lymphoma and treated with HCT-ASCT.    18 patients (8 F/10 M), all immunocompetent, were included in the study. Mean age at HCT-ASCT was 59.17 (range 41 years-73 years). Median Karnofsky Performance status before HCT-ASCT was 90. At diagnosis, 8/18 had PVRL, 9/18 Primary Central Nervous Cells Lymphoma (PCNCL), 1/18 systemic lymphoma. Before HCT-ASCT, patients had received a median number of 1 line of treatment including high-dose methotrexate for all patients. All the patients received a thiotepa-based HCT. After HCT-ASCT, 14 patients experienced a complete response. No« toxic death » occurred. After a mean follow-up of 34.5 months (range: 8-82), 7/18 patients had recurrences (3 VRL relapses, 1 cerebral relapse, 3 ocular and cerebral relapses). The 1 year survival rate was 94.4%.    Intensive chemotherapy followed by autologous stem cell transplant is an aggressive therapeutic approach but appear to give interesting results in young and fit patients with recurrent refractory vitreoretinal lymphoma.  This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017. 
RD 3/3/2021